TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Only female patients are eligible~2. Patients must be 18 years of age or older~3. Patients must have Androgenic Alopecia Grade I-II by Ludwig Classification~4. Patients must have been on stable birth control if premenopausal.~5. Patients are able and willing to provide written informed consent after the nature of the study is fully explained~Exclusion Criteria:~1. Patients with clinically abnormal hematology, serum chemistry, or screening laboratory results as reviewed by the Principal Investigator~2. Patients who have undergone topical and systemic therapies for hair loss 3 months prior to the procedure~3. Patients who have used any cosmetic product meant to address hair loss 3 months prior to enrollment~4. Patients taking anti-rheumatic disease medication (including methotrexate or other anti-metabolites) within the 3 months prior to study entry.~5. Patients previously having undergone hair transplant surgery prior to study entry~6. Patients who are pregnant or currently breast-feeding children as Rogaine for Women is contra indicated for these women~7. Patients who have taken spironolactone in the 3 months prior to study participation~8. Patients with systemic, rheumatic or inflammatory disease or who are immunosuppressed~9. Patients with ongoing infectious disease, including HIV and hepatitis~10. Patients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer, or diabetes~11. Patients participating in a study of an experimental drug or medical device within 30 days of study entry~12. Patients with history of platelet disorders, bone marrow aplasia, sepsis, or cancer in the last 5 years.~13. Patients taking antiaggregating therapy~14. Patients on anticoagulant therapy~15. Patients with tendency to keloid formation~16. Patients with uncompensated diabetes~17. Patients with active skin disease or skin infection at intended treatment areas

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Platelet Rich Plasma first, then Minoxidil Foam (Type: EXPERIMENTAL): Subjects will be randomized into the Platelet Rich Plasma group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Minoxidil Foam for 12 weeks.
- Minoxidil Foam first, then Platelet Rich Plasma (Type: EXPERIMENTAL): Subjects will be randomized into the Minoxidil Foam group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Platelet Rich Plasma.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bleeding Pattern Difference Between Levonorgestrel Intrauterine System (LNG-IUS) and Copper Intrauterine Devices (IUDs) Immediately Inserted After Abortion

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Reproductive women in good general health and requesting long-term contraception~* Applied the Cu-IUD or LNG-IUS immediately after first trimester surgical abortion~* History of regular cyclic menstrual periods~* Written ICF was obtained~Exclusion Criteria:~* Suspected septic abortion and incomplete abortion, as well as missed abortion~* The contraindications and warnings of the respective Summary of Product Characteristics of Mirena or prescribing information of Cu-IUDs must be followed

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): The MIRENA intrauterine delivery system (initial release rate: 20 μg LNG /24 h)
- Group 2 (Type: None): Copper IUDs with different shape and with or without drugs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must be diagnosed with HCC either pathologically or by the American Association for the Study of Liver Diseases (AASLD) radiographic criteria (Bruix Hepatology 2011). The criteria specifies CT or MRI intense arterial uptake followed by washout of contrast in the venous-delayed phases. Any atypical lesions must be confirmed by biopsy.~* A single liver lesion with tumor size ≥ 3 cm as defined as maximal diameter in the axial dimension on MRI. Included in the measurement are both enhancing and non-enhancing components of the lesion.~* Maximum tumor size of 7 cm as defined as maximal diameter in the axial dimension on MRI.~* Age ≥ 18 years~* Child-Pugh class A or B7 without ascites~* ECOG score 0~* No prior treatment of current HCC. However, recurrent HCC after resection may be included.~* Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* Pregnancy which will be assessed via pregnancy test prior to TACE and repeated prior to SBRT.~* Metastatic disease outside of the liver~* Vascular invasion as evidenced by vessel occlusion or radiographic evidence of tumor thrombus.~* Contraindications to MRI, including claustrophobia, metallic implants, and pacemakers~* Tumor for which adequate radiation dosage cannot be safely delivered (see dose constraints below)~* Prior therapeutic radiation therapy to the abdomen and/or lower thorax as defined as below the carina to the pelvic inlet.~* Inability to provide informed consent based on persistent lack of understanding, inability to find adequate translation, impaired mental status such as mental retardation, drug induced, or traumatic brain injury.~* Multiple liver tumors making the patient a BCLC Stage B~* Prior treatment, except for surgical resection, to the lesion being targeted in the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants with HCC (Type: EXPERIMENTAL): Participants with HCC with a lesion greater than 3 cm treated with TACE/SBRT combination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hepatic Effects of Gastric Bypass Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. BMI \> 40.~2. Documented failed non-surgical treatment for morbid obesity.~3. Ability to undergo long-term follow-up after LGBS.~Exclusion Criteria:~1. BMI \< 40.~2. Subject age \< 18 years.~3. Inability to undergo long-term follow-up after LGBS (living distance \> 300 miles).~4. Patients with known ESLD.~5. Patients found to have evidence of ESLD during preoperative evaluation for LGBS including portal hypertension, ascites, and coagulopathy.~6. Patients with known iodine sensitivity or allergy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- liver function (Type: OTHER): Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients with histologically or cytologically confirmed advanced solid malignancy or Lymphoma~Relapsed or refractory disease after at least 1 prior systemic treatment for the primary malignancy and not a candidate for other curative treatment.~Adequate hematologic status~Adequate coagulation function~Adequate hepatic function~Adequate renal function~Exclusion Criteria:~Known primary tumors of central nervous system disease~Known active brain metastases~Known cardiopulmonary disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Hu5F9-G4) (Type: EXPERIMENTAL): Hu5F9-G4 monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EMRI SureScan™ Clinical Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has, or is at risk of having, a heart beat that is too slow and his/her doctor has determined he/she needs a pacemaker.~* Subject available for follow-up at study center for length of study.~* Subject able and willing to undergo elective MRI scanning without sedation.~Exclusion Criteria:~* Subject has, or is at risk of having, a heart beat that is too fast and his/her doctor has determined he/she needs an implantable cardioverter defibrillator (ICD).~* Subject needs or will need another MRI-scan, other than those required by the study, during the required study follow-up period.~* Pregnant women, or women of child bearing potential who are not on a reliable form of birth control.~* Subject with exclusion criteria required by local law.~* Subject who intends to participate in another clinical study during this clinical study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MRI group (Type: ACTIVE_COMPARATOR): The MRI group underwent a one-hour MRI scan at the 9-12 weeks post-implant follow-up.
- Control group (Type: OTHER): The control group waited for one hour (no MRI) at the 9-12 weeks post-implant follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Treatment of Articular Repair (STAR)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Provided written informed consent~* Documented history of at least one Grade III or Grade IV defect (modified Outerbridge classification) on the medial or lateral femoral condyle or trochlea~* Failed prior treatment for articular cartilage defects of the knee, e.g. inadequate response to a non- ACI surgical procedure to treat the lesion, within past 3 yrs~* Patient reported overall knee condition of 5 or less on the Modified Cinn Rating System~* patients must have had a cartilage defect located on the medial or lateral femoral condyle or trochlea which had an inadequate response to a prior arthroscopic or other non-Carticel surgical repair procedure~Exclusion Criteria:~* see above

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin Versus Estrogen for the Treatment of Hot Flashes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Menopausal women between ages 35-60~2. Must experience 7-20, moderate-severe hot flashes/day or 50-140 moderate-severe hot flashes/week for greater than two months~3. Must have had a bilateral salpingo-oopherectomy for \>12 months or amenorrhea\>6 months or #4 (below)~4. Has an FSH\>30 mIU/ml~5. Must have a signed informed consent~6. Able to function independent in all activities of daily living and be capable of reliable documentation~Exclusion Criteria:~1. Any contraindication to estrogen and progesterone replacement therapy~2. History of an MI, stroke, and/or functional decline.~3. Fails to record data in the hot flash diary\>3 days during the 2 week baseline period.~4. Unable or willing to make required visits at the specified times over the course of therapy.~5. History of any malignancies or undiagnosed vaginal bleeding.~6. History of chronic liver, gallbladder, chronic renal, cardiac or endocrine diseases

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antipsychotic Discontinuation in Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Dementia, either sex, age 50-95 years~* Probable Alzheimer's disease~* Intellectual impairment present for at least 6 months~* Mini Mental State Exam (MMSE) score of 5-26 for outpatients and 2-26 for nursing home patients~* Availability of informant who has had direct contact with the patient for an average of at least once every week during the 3 months prior to study entry~* Meets Neuropsychiatric Inventory (NPI) criteria for either (1) psychosis, or (2) agitation/aggression~* Able to mobilize independently (if wheelchair-bound, the patient must be able to self-propel)~* Free of psychotropic medication (or able to tolerate washout) for at least 1 week prior to study entry. Low dose antidepressants and sedative/hypnotics allowed if they cannot be washed out and the dose remains stable for the study duration~* Expected to complete the study (including all efficacy evaluations) and be without major sensory impairment that would prevent participation in any aspect of the study~Exclusion Criteria:~* Current primary Axis I psychiatric disorder other than AD~* Substance abuse or dependence currently, or within the past year~* Dementia due to head trauma~* History of allergy to risperidone or intolerance to risperidone~* Diffuse Lewy body disease~* History of seizure disorder, infectious encephalitis, Parkinson's disease, central nervous system (CNS) neoplasm, tardive dyskinesia, stroke, transient ischemic attack (TIA) or uncontrolled atrial fibrillation~* Use of monoamine oxidase inhibitors (MAOIs) and unable to undergo 3-week washout; patients also may not take MAOIs for 2 weeks after completing the study~* In treatment with (a) depot antipsychotic within 2 weeks of the screening visit~* Untreated or incompletely treated hypothyroidism~* Active, unstable medical condition that requires active medication adjustment or surgery~* Need for electroconvulsive treatment (ECT)~* Significant risk for harm to themselves or others as a result of randomization to placebo~* History of malignant neoplasm during the last 5 years

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Risperidone-risperidone (Type: OTHER): Risperidone for 16 weeks followed by risperidone for 16 weeks
- Risperidone-Placebo (Type: OTHER): Risperidone for 16 weeks followed by placebo for 16 weeks
- Placebo-Placebo (Type: OTHER): Placebo for 16 weeks followed by placebo for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: JKB-121 for the Treatment of Nonalcoholic Steatohepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years~2. Provision of written informed consent~3. Biopsy-proven NASH within 12 months or at screening~4. ALT \> 40 U/L for women and \> 60 U/L for men at screening and at least once in the previous 12 months.~5. HBA1C of ≤ 9.0~Exclusion Criteria:~1. Any chronic liver disease other than NASH~2. Cirrhosis, as assessed clinically or histologically~3. Presence of vascular liver disease~4. BMI ≤ 25 kg/m2~5. Excessive alcohol use (\> 20 g/day) within the past 2 years~6. AST or ALT \> 250 U/L.~7. Type 1 diabetes mellitus~8. Bariatric surgery in the past 5 years.~9. Weight gain of \> 5% in past 6 months or \> 10% change in past 12 months.~10. Contraindication to MRI~11. Inadequate venous access~12. HIV antibody positive, hepatitis B surface antigen positive (HBsAg), or Hepatitis C virus (HCV) RNA positive.~13. Receiving an elemental diet or parenteral nutrition~14. Chronic pancreatitis or pancreatic insufficiency~15. Any history of complications of cirrhosis~16. Concurrent conditions:~    * Inflammatory bowel disease~   * Significant cardiac disease~   * chronic infection or immune mediated disease~   * Any malignant disease~   * Prior solid organ transplant~   * Any other concurrent condition which, in the opinion of the investigator, could impact adversely on the subject participating or the interpretation of the study data.~17. Concurrent medications which may treat NASH~18. HbA1C \> 9.0%~19. Pregnancy or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): JKB 121, 5 mg twice daily
- B (Type: ACTIVE_COMPARATOR): JKB 121, 10 mg twice daily
- C (Type: PLACEBO_COMPARATOR): Identical appearing placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has a diagnosis of RA based upon the American College of Rheumatology (ACR) 1987 Revised Criteria.~* The patient must have had an inadequate response to methotrexate and have active disease, as defined by both: ≥6 joints tender or painful on motion; and ≥6 joints swollen; and fulfills 1 of the following 2 criteria at Screening: 1.ESR (Westergren method) \>28 mm in the local laboratory. 2. CRP \>7 mg/L in the central laboratory.~* No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.~* The patient must have been on a stable dose of 7.5 mg to 25 mg weekly of methotrexate and washed out of all other DMARDs.~Exclusion Criteria:~* Blood dyscrasias including confirmed: 1. Hemoglobin \<9 g/dL or Hematocrit \<30%; 2. White blood cell count \<3,000 cu.mm. Absolute neutrophil count \<1,200 cu.mm; 4. Platelet count \<100,000/L~* History of any other autoimmune rheumatic disease other than Sjogren's syndrome~* No malignancy or history of malignancy.~* History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug~* Patients who have failed any TNFi for either lack of efficacy or a TNFi mechanism related adverse event.~* Patients who have previously received adalimumab therapy for any reason.~* Patients who are contraindicated for treatment with adalimumab in accordance with the approved local label.~* Patients meeting the New York Heart Association Class III and Class IV Congestive Heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5mg (Type: EXPERIMENTAL): None
- 10 mg (Type: EXPERIMENTAL): None
- Placebo Sequence 1 (Type: PLACEBO_COMPARATOR): None
- Placebo Sequence 2 (Type: PLACEBO_COMPARATOR): None
- adalimumab (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Double Blind Study Evaluating Duloxetine in Outpatients With MDD and Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Major Depressive Disorder according to DSM-IV criteria with at least one previous depressive episode in the patient's medical history~* Painful physical symptoms as measured by the Brief Pain Inventory-Short Form~Exclusion Criteria:~* Any anxiety disorder as a primary diagnosis within the past 6 months (including panic disorder, OCD, PTSD, generalized anxiety disorder and social phobia)~* Any diagnosis of bipolar disorder, schizophrenia, or other psychotic disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete